Table 4.
Odds of Receiving rt‐PA at a PSC Versus Non‐PSC, by Race, in the NIS 2004–2010
| Race | Treatment Rate | Unadjusted | Model 1a | Model 2b | Model 3c | |
|---|---|---|---|---|---|---|
| PSC (%) | Non‐PSC (%) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| White | 7.60 | 2.65 | 3.03 (2.65 to 3.45) | 1.81 (1.60 to 2.05) | 1.73 (1.50 to 2.00) | 1.73 (1.50 to 2.00) |
| Black | 4.76 | 1.97 | 2.49 (2.01 to 3.09) | 1.63 (1.30 to 2.05) | 1.46 (1.15 to 1.85) | 1.47 (1.16 to 1.87) |
| Hispanic | 7.07 | 2.41 | 3.08 (2.40 to 3.94) | 1.77 (1.34 to 2.35) | 1.55 (1.17 to 2.05) | 1.54 (1.16 to 2.05) |
| Othersd | 7.19 | 2.48 | 3.05 (2.35 to 3.97) | 2.37 (1.82 to 3.10) | 2.00 (1.50 to 2.67) | 1.99 (1.49 to 2.66) |
APR‐DRG indicates all patient refined‐diagnosis related group; NIS, Nationwide Inpatient Sample; OR, odds ratio; PSC, Primary Stroke Center; rt‐PA, recombinant tissue plasminogen activator.
Adjusted for: year, age, sex, primary expected payer, median income quartiles by ZIP code, region, teaching hospital, urban hospital location, and volume of acute ischemic stroke annually at hospital.
Model 1+each of the 29 Agency for Healthcare Quality and Research (individual) comorbidities.
Model 2+APR‐DRG measure of disease severity to estimate the likelihood of dying during the hospitalization (minor, moderate, major, and extreme likelihoods of dying).
Others includes Asian/Pacific Islander, Native American, and other.